Rapport Therapeutics, Inc.: Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the ...

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarte ...
The Manila Times

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures ...
Frontiers

Cortical stimulation and epilepsy: Network physiology insights for diagnosis and therapy

The field of epilepsy research has rapidly evolved with an appreciation that seizures arise from dysfunctions in distributed ...
Healio

First seizure clinic provides visit, pediatric epilepsy diagnosis in less than a week

The first seizure clinic model enabled rapid diagnosis and treatment for children with epilepsy, according to data presented ...

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, ...
Investing

NeuroPace reports 77% seizure reduction in epilepsy device trial

The data, presented at the American Epilepsy Society meeting, demonstrated statistically significant seizure reduction compared to baseline (p According to the press release, approximately 30% of ...
Morningstar

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

-- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to ...
Yahoo Finance

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

MOUNTAIN VIEW, Calif., December 08, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the ...
Medical Xpress

First seizure clinic speeds time to diagnosis with pediatric epilepsy

Children referred to a first seizure clinic (FSC) see a neurologist epilepsy specialist within one week, according to a study presented at the annual meeting of the American Epilepsy Society, held ...
Kaleido Scope

Understanding epilepsy: Types of seizures, symptoms and first aid

Epilepsy is a common neurological disorder that affects millions of people worldwide. Characterized primarily by seizures, epilepsy can present in a variety of ways depending on the individual and the ...
Kaleido Scope

6 seizure symptoms and their warning signs

“It’s all about the brain,” said Jennifer DeWolfe, D.O., professor in the UAB Department of Neurology. “Seizure manifestations are stereotyped, so the same symptoms occur with each seizure that ...
Hosted on MSN

Xenon Pharmaceuticals’ Phase 3 Study on XEN1101: A Potential Game-Changer in Seizure Treatment

Xenon Pharmaceuticals ((XENE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...